You are right in saying that the top line growth is slightly moderated. I think this was not very far from expectations. Previous calendar year was a year when many companies bore the brunt of inflation after the Russia-Ukraine conflict started and commodities rose.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the